Human Liver Spheroids from Peripheral Blood for Liver Disease Studies
January 27th, 2023
2.3K views
Here we present a non-genetic method to generate human autologous liver spheroids using mononuclear cells isolated from steady-state peripheral blood.
Overview
This article presents a non-genetic method for generating human autologous liver spheroids using mononuclear cells from peripheral blood. This technique has significant implications for research in toxicology, cancer, and drug discovery.
Key Study Components
Area of Science
- Neuroscience
- Regenerative Medicine
- Cell Biology
Background
- Human liver spheroids can be generated from autologous sources.
- This method addresses the shortage of primary human hepatocytes.
- BDPC-derived human hepatocytes are utilized in this technique.
- Applications extend to regenerative medicine and therapy for acute liver failure.
Purpose of Study
- To demonstrate a method for generating liver spheroids.
- To explore applications in toxicology and drug discovery.
- To provide a solution for the shortage of primary human hepatocytes.
Methods Used
- Preparation of hepatoblast KnockOut serum replacement dimethyl sulfoxide (KSR DMSO) medium.
- Preparation of hepatocyte maturation medium.
- Aliquoting medium and adding hepatocyte growth factor (HGF) and oncostatin M (OCM).
- Maintaining final concentrations of 10 or 20 nanograms per milliliter for each medium change.
Main Results
- Successful generation of human liver spheroids from autologous sources.
- Demonstration of the procedure by Dr. Anne-Katherin Schott.
- Potential applications in regenerative medicine highlighted.
- Method provides a viable alternative to using primary human hepatocytes.
Conclusions
- The non-genetic method for generating liver spheroids is effective.
- This technique can significantly impact research in various fields.
- Further exploration of applications in therapy for liver failure is warranted.
Frequently Asked Questions
What are liver spheroids?
Liver spheroids are three-dimensional clusters of liver cells that mimic the structure and function of liver tissue.
Why use autologous sources for spheroid generation?
Using autologous sources reduces the risk of immune rejection and provides a more relevant model for patient-specific studies.
What is the significance of using BDPC-derived human hepatocytes?
BDPC-derived human hepatocytes help overcome the limitations associated with the availability of primary human hepatocytes.
How can liver spheroids be applied in drug discovery?
Liver spheroids can be used to study drug metabolism and toxicity in a more physiologically relevant context.
Who is Dr. Anne-Katherin Schott?
Dr. Anne-Katherin Schott is the project leader demonstrating the spheroid generation procedure in this study.
What are the advantages of this non-genetic method?
The non-genetic method allows for the generation of liver spheroids without the ethical concerns associated with genetic manipulation.
Executive Industry Relevance
Human liver spheroids derived from peripheral blood enable scalable, physiologically relevant models for liver disease research and drug discovery. This approach addresses the persistent shortage of primary human hepatocytes, supporting predictive confidence in early-stage compound evaluation and mechanistic de-risking. The method enhances translational continuity by providing autologous, in vivo-like systems for toxicology and disease modeling.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Supports interrogation of hepatic disease mechanisms using patient-derived, 3D cellular systems.
- Enables functional validation of liver-specific targets in a physiologically relevant microenvironment.
- Facilitates mechanistic de-risking by modeling human liver biology more accurately than 2D cultures.
Screening & Assay Development
- Provides reproducible, scalable 3D liver spheroids for compound screening and toxicity assays.
- Improves assay standardization and quantitative output through consistent spheroid formation and marker expression.
- Enables reliable evaluation of drug-induced hepatotoxicity in a human-relevant context.
Translational & Preclinical Research
- Aligns with disease-relevant modeling for liver pathologies and drug response prediction.
- Supports continuity from discovery through preclinical validation by using autologous, blood-derived cells.
- Reduces translational risk by providing in vitro systems that recapitulate in vivo liver architecture and function.
Pipeline & Workflow Integration
This method integrates into the discovery-to-preclinical continuum by enabling early hypothesis testing, target validation, and compound screening in human-relevant liver models.
- Discovery Biology: Facilitates hypothesis testing and pathway clarification in hepatic systems using autologous spheroids.
- Screening: Delivers assay-ready, reproducible 3D cultures for quantitative drug response and toxicity measurements.
- Analytics: Supports immunophenotyping and morphological analysis to compare differentiation stages and functional outputs.
- Translational Research: Provides a bridge to preclinical studies by modeling disease and drug effects in a physiologically relevant system.
- Enterprise Reuse: Offers a standardized, scalable platform for repeated use across multiple R&D programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in liver disease and toxicity studies.
- Operational Value: Enables standardization, reproducibility, and scalability of 3D liver models from accessible blood sources.
- Strategic Value: Improves go/no-go decision-making and capital efficiency by providing robust early-stage data.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of liver-targeted therapeutics.
Implementation Considerations
- Requires expertise in stem cell differentiation and 3D culture techniques.
- Needs access to specialized media, low-attachment plates, and imaging infrastructure.
- Demands cross-team standardization for reproducible spheroid generation and analysis.
- Adaptation may be needed for different donor sources or disease contexts.
- Dependent on quality of blood-derived pluripotent stem cells and immunophenotyping reagents.
Biopharma FAQs
Why is null hypothesis testing important for liver spheroid target validation?
Null hypothesis testing enables objective assessment of whether observed functional changes in BD-PSC-derived liver spheroids are due to specific interventions or random variation, supporting robust target validation in early discovery.
How does independent variable isolation fit into spheroid-based discovery workflows?
Isolating variables such as differentiation stage or compound exposure in 3D liver spheroid cultures allows teams to attribute observed effects directly to experimental conditions, enhancing mechanistic clarity in the discovery pipeline.
What do quantitative dependent variable measurements enable in liver spheroid assays?
Quantitative measurements of marker expression and morphological changes in spheroids provide actionable data for comparing differentiation efficiency, functional maturity, and drug response across experimental arms.
Why do replication requirements matter for cross-functional liver model collaboration?
Replication ensures that spheroid formation, differentiation, and functional outputs are consistent across teams, enabling reliable data sharing and integration in multi-site R&D environments.
What statistical analysis capabilities are required before implementing spheroid-based assays?
Robust statistical tools are needed to analyze immunophenotyping and imaging data, compare experimental groups, and validate reproducibility before integrating spheroid assays into broader screening or translational workflows.
Chapters in this video
0:05
Introduction
0:58
Preparation of Hepatocyte Differentiation Media
1:27
Culturing Hepatic Cells Differentiated from Blood-Derived Pluripotent Stem Cells (BD-PSCs)
2:14
3D Spheroid Hepatic Differentiation
3:34
Immunofluorescence Analysis of Newly Generated 2D Liver Cell Cultures
4:59
Live Staining of Newly Formed Liver Spheroids
6:01
Examination of Spheroids Using a Fluorescence Microscope
7:32
Results: Differentiation of Human BD-PSCs into Endoderm/Hepatic Progenitor Cells and Hepatocytes
9:11
Conclusion
